Mineralys Therapeutics, Inc. Stock price

Equities

MLYS

US6031701013

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-23 pm EST 5-day change 1st Jan Change
15.88 USD +1.40% Intraday chart for Mineralys Therapeutics, Inc. +2.58% +84.65%
Sales 2023 * - Sales 2024 * - Capitalization 774M
Net income 2023 * -83M Net income 2024 * -126M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-6.88 x
P/E ratio 2024 *
-5.53 x
Employees 12
Yield 2023 *
-
Yield 2024 *
-
Free-Float 51.21%
More Fundamentals * Assessed data
Dynamic Chart
Sector Update: Health Care Stocks Ease in Late Afternoon MT
Sector Update: Health Care MT
Mineralys Therapeutics Secures $120 Million Financing Through Private Placement; Shares Rise MT
Mineralys Therapeutics, Inc. announced that it expects to receive $119.999925 million in funding from TCG Crossover Management, LLC, OrbiMed Advisors LLC, RA Capital Management, L.P., Samsara BioCapital LLC CI
Mineralys Therapeutics Names Minji Kim as Chief Business Officer MT
Mineralys Therapeutics, Inc. Appoints Minji Kim as Chief Business Officer CI
Mineralys Therapeutics Reports Dosing of First Subject in Second Lorundrostat Trial in Hypertension MT
Mineralys Therapeutics, Inc. Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension CI
Mineralys Therapeutics, Inc.(NasdaqGS:MLYS) added to NASDAQ Biotechnology Index CI
Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 CI
Mineralys Therapeutics, Inc Presents Data from the Target-HTN Phase 2 Trial That Further Defines an Endotype-Specific Targeted Approach for Treating Uncontrolled or Resistant Hypertension with Lorundrostat CI
Mineralys Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Mineralys Therapeutics, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Mineralys Therapeutics, Inc. Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting CI
Mineralys Therapeutics, Inc. Expands Its Board CI
More news
1 day+0.03%
1 week+1.29%
Current month+43.72%
1 month+65.93%
3 months+150.08%
6 months+20.89%
Current year+82.33%
More quotes
1 week
14.73
Extreme 14.73
15.96
1 month
9.32
Extreme 9.32
15.96
Current year
7.95
Extreme 7.95
15.96
1 year
5.85
Extreme 5.85
20.10
3 years
5.85
Extreme 5.85
21.98
5 years
5.85
Extreme 5.85
21.98
10 years
5.85
Extreme 5.85
21.98
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 20-10-31
Director of Finance/CFO 46 22-02-28
Chief Operating Officer - 21-02-28
Members of the board TitleAgeSince
Director/Board Member 56 21-01-31
Director/Board Member 68 23-09-12
Director/Board Member 58 21-01-31
More insiders
Date Price Change Volume
24-02-23 15.88 +1.40% 63 151
24-02-22 15.66 +2.69% 202,341
24-02-21 15.25 -0.33% 109,195
24-02-20 15.3 -1.16% 146,128
24-02-16 15.48 +3.34% 251,517

Delayed Quote Nasdaq, February 23, 2024 at 01:53 pm EST

More quotes
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.66 USD
Average target price
35 USD
Spread / Average Target
+123.50%
Consensus
  1. Stock
  2. Equities
  3. Stock Mineralys Therapeutics, Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer